Publications by authors named "Pearl Samson"

Claim this Profile
S
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
Aditya H Gaur, Edmund V Capparelli, Katherine Calabrese, Kristin Baltrusaitis, Mark A Marzinke, Pearl Samson

Lancet HIV· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age.
Mina Nikanjam, Lana Tran, Ellen G Chadwick, Mutsa Bwakura-Dangarembizi, Carolyn Bolton Moore, Pearl Samson

AIDS· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study.
Adrie Bekker, Edmund V Capparelli, Avy Violari, Mark F Cotton, Mae Cababasay, Pearl Samson

Lancet HIV· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.
Paul Krogstad, Pearl Samson, Edward P Acosta, Jack Moye, Ellen Townley

J Pediatric Infect Dis Soc· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of maraviroc in neonates.
Julia C Rosebush, Brookie M Best, Ellen G Chadwick, Kevin Butler, John Moye, Pearl Samson

AIDS· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Virologic Failure and Nonnucleoside Reverse Transcriptase Inhibitor Resistance Found in Antiretroviral-Naive Children Infected With Human Immunodeficiency Virus and Given Efavirenz-Based Treatment.
Nikki Higa, Amy Pelz, Donald Birch, Ingrid A Beck, Tatiana Sils, Pearl Samson

J Pediatric Infect Dis Soc· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis.
Tammy Meyers, Pearl Samson, Edward P Acosta, Jack Moye, Ellen Townley

AIDS· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years.
Mutsa Bwakura Dangarembizi, Pearl Samson, Edmund V Capparelli, Carolyn Bolton Moore, Patrick Jean-Philippe

J Acquir Immune Defic Syndr· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection.
Carolyn Bolton Moore, Edmund V Capparelli, Pearl Samson, Mutsa Bwakura-Dangarembizi, Patrick Jean-Philippe

AIDS· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Towards early inclusion of children in tuberculosis drugs trials: a consensus statement.
Sharon Nachman, Amina Ahmed, Farhana Amanullah, Mercedes C Becerra, Radu Botgros, Pearl Samson

Lancet Infect Dis· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A.
Richard M Rutstein, Pearl Samson, Terry Fenton, Courtney V Fletcher, Jennifer J Kiser

Pediatr Infect Dis J· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents.
Jennifer J Kiser, Richard M Rutstein, Pearl Samson, Bobbie Graham, Grace Aldrovandi

AIDS· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected children.
Courtney V Fletcher, Jaime G DeVille, Pearl M Samson, John H Moye, Joseph A Church

J Allergy Clin Immunol· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140).
William T Shearer, Jaime G DeVille, Pearl M Samson, John H Moye, Courtney V Fletcher

J Allergy Clin Immunol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis